PTH and cancer: Current medical treatments for osteoporosis commonly encompass diphosphonate, calcitonin, estrogen receptor modulators, and parathyroid hormone (PTH); accordingly, such treatments can cause undesired side effects, including gastrointestinal responses, renal toxicity (Xu et al., 2013), hypocalcemia (Smith et al., 2009), and an increased risk of cancer (Choi et al., 2020).